A Protein Tyrosine Phosphatase 1B Activity Inhibitor from the Fruiting Bodies of Ganoderma lucidum (Fr.) Karst and Its Hypoglycemic Potency on Streptozotocin-Induced Type 2 Diabetic Mice

• Published in: Journal of agricultural and food chemistry Vol. 59; no. 12; pp. 6492 - 6500
• Main Authors: Teng, Bao-Song, Wang, Chen-Dong, Yang, Hong-Jie, Wu, Jia-Sheng, Zhang, Dan, Zheng, Min, Fan, Zhao-Hua, Pan, Deng, Zhou, Ping
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 22.06.2011
• Subjects: Animals; Bioactive Constituents; Biological Factors - administration & dosage; Biological Factors - analysis; Biological Factors - isolation & purification; blood glucose; Blood Glucose - analysis; Diabetes Mellitus, Type 2 - drug therapy; Disease Models, Animal; drug therapy; Enzyme Inhibitors - administration & dosage; Enzyme Inhibitors - analysis; Enzyme Inhibitors - isolation & purification; foods; fruiting bodies; Fruiting Bodies, Fungal - chemistry; Ganoderma lucidum; Humans; Hypoglycemic Agents - administration & dosage; Hypoglycemic Agents - analysis; Hypoglycemic Agents - isolation & purification; inhibitory concentration 50; Male; metformin; Mice; molecular weight; noninsulin-dependent diabetes mellitus; Protein Tyrosine Phosphatase, Non-Receptor Type 1 - antagonists & inhibitors; protein-tyrosine-phosphatase; proteoglycans; Reishi - chemistry; Streptozocin; toxicity; Ganoderma lucidum; protein tyrosine phosphatase 1B; inhibitor; diabetes

Inhibition of protein tyrosine phosphatase 1B (PTP1B) activity has been considered to be a promising therapy approach to treat type 2 diabetes. In this work, a novel PTP1B activity inhibitor, named FYGL (Fudan–Yueyang–G. lucidum), was screened from the fruiting bodies of Ganoderma lucidum and showed...